|Articles|April 10, 2014

uniQure Announces Management Changes

Author(s)BioPharm International Editors

uniQure appoints a new COO and vice president, Medical affairs.

uniQure, a human gene therapy company, reported the appointment of Eric Goossens as its new COO. Goossens has 15 years of experience in management and leadership for technology-based companies, including the biopharmaceutical industry.

In addition, uniQure appointed Deya Corzo, MD, as vice president, Medical Affairs for the US as of April 1, 2014. Goossens joins uniQure from Dätwyler Pharma Packaging Belgium N.V where he was site director for three years. Corzo previously worked at Celgene, as executive director, Medical Affairs/Oncology from 2012 to 2014.

Source: uniQure

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

Close-up of an older person's hands, with the thumb of one hand pressing into the palm of the other, against a blurred teal background. | Image Credit: © eyepark - stock.adobe.com

October 2nd, 2026

Artiva to Present AlloNK Data Showing CAR T-Like B-Cell Depletion in Rheumatologic Diseases at ACR 2026

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.

October 1st, 2026

Former FDA Oncology Reviewer Paz Vellanki on Novel Endpoints and Early FDA Engagement Under CDER's ARC Program

Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.

3D illustration of a single-stranded RNA molecule with nucleotide bases extending from a twisting backbone, shown in purple, pink, and yellow against a black background. | Image Credit: © Dr_Microbe - stock.adobe.com

October 1st, 2026

Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD

Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.

September 30th, 2026

The BioPharm Brief: Pills, Skin, and Biosimilars

Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.

Injection pens lying next to white oral tablets on a blue surface. | Image Credit: © Andreas Prott - stock.adobe.com

September 30th, 2026

Wegovy Pill Delivers 4.1% Weight Loss in Patients Switching From Injectables, Real-World OCTANE Data Show

In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.

September 29th, 2026

The BioPharm Brief: Deals, Data, and a $2 Billion Bet

Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.

Three injection pens labeled Wegovy, Ozempic, and Victoza crossed behind a bottle of Wegovy semaglutide 1.5 mg tablets on a white background. | Image Credit: © silukstockimages - stock.adobe.com

September 29th, 2026

Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion

Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.